Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-Current Deffered Revenue (2016 - 2025)

Spero Therapeutics' Non-Current Deffered Revenue history spans 8 years, with the latest figure at $12.6 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue rose 6.12% year-over-year to $12.6 million; the TTM value through Sep 2025 reached $12.6 million, up 6.12%, while the annual FY2024 figure was $12.2 million, 12.88% up from the prior year.
  • Non-Current Deffered Revenue reached $12.6 million in Q3 2025 per SPRO's latest filing, roughly flat from $12.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $23.8 million in Q3 2023 to a low of $8.8 million in Q4 2021.
  • Average Non-Current Deffered Revenue over 5 years is $13.5 million, with a median of $12.2 million recorded in 2024.
  • Peak YoY movement for Non-Current Deffered Revenue: crashed 59.46% in 2024, then soared 39.1% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $8.8 million in 2021, then rose by 10.87% to $9.7 million in 2022, then increased by 11.13% to $10.8 million in 2023, then rose by 12.88% to $12.2 million in 2024, then grew by 2.91% to $12.6 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Non-Current Deffered Revenue are $12.6 million (Q3 2025), $12.6 million (Q2 2025), and $12.6 million (Q1 2025).